The Science Hat Podcast – Full version

Episode 1. Who is Clarity and what drives our team forward?

Episode 2. Where do radiopharmaceuticals fit in the current cancer treatment landscape?

Episode 3. Targeted Copper Theranostics (TCTs) – The perfect pairing of Cu-64 for imaging and Cu-67 for treatment

Episode 4. What differentiates Clarity from other radiopharmaceutical companies?

Episode 5. SAR-bisPSMA – Optimised with two PSMA-targeting agents to better image and treat prostate cancer.

Episode 6.  SAR-Bombesin – Targeting a new protein in prostate cancer 

Episode 7. Challenges and opportunities in the emerging radiopharmaceutical market

Episode 8. Clarity maintains strong momentum as multiple clinical programs progress into Phase III trials.